Number of the records: 1  

A forskolin-mediated increase in cAMP promotes T helper cell differentiation into the Th1 and Th2 subsets rather than into the Th17 subset

  1. 1.
    0583605 - BFÚ 2024 RIV NL eng J - Journal Article
    Daďová, Petra - Mikulová, Antónia - Jaroušek, Radim - Chorvátová, Michaela - Uldrijan, S. - Kubala, Lukáš
    A forskolin-mediated increase in cAMP promotes T helper cell differentiation into the Th1 and Th2 subsets rather than into the Th17 subset.
    International Immunopharmacology. Roč. 125, DEC 2023 (2023), č. článku 111166. ISSN 1567-5769. E-ISSN 1878-1705
    Institutional support: RVO:68081707
    Keywords : dependent protein-kinase * cyclic-amp * genetic architecture * pde4 inhibitor * responses * memory * naive * lymphocytes * expression * modulators
    OECD category: Immunology
    Impact factor: 5.6, year: 2022
    Method of publishing: Open access
    https://www.sciencedirect.com/science/article/pii/S1567576923014923?via%3Dihub

    The adenylyl cyclase (AC) signaling pathway is suggested to be a key regulator of immune system functions. However, specific effects of cyclic adenosine monophosphate (cAMP) on T helper (Th) cell differentiation and functions are unclear. The involvement of cAMP in the Th cell differentiation program, in particular the development of Th1, Th2, and Th17 subsets, was evaluated employing forskolin (FSK), a labdane diterpene well known as an AC activator. FSK mediated an elevation in Th1-specific markers reinforcing the Th1 cell phenotype. The Th2 differentiation was supported by FSK, though cell metabolism was negatively affected. In contrast, the Th17 immunophenotype was severely suppressed leading to the highly specific upregulation of CXCL13. The causality between FSK-elicited cAMP production and the observed reinforcement of Th2 differentiation was established by using AC inhibitor 2 ',5 '-dideoxyadenosine, which reverted the FSK effects. Overall, an FSK-mediated cAMP increase affects Th1, Th2 and Th17 differentiation and can contribute to the identification of novel therapeutic targets for the treatment of Th cell-related pathological processes.
    Permanent Link: https://hdl.handle.net/11104/0351615

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.